Bacopa Enlighten

AOR04025

Supports cognitive function

  • A powerful plant extract for improving mental function
  • Helps improve memory and focus
  • Protects the nervous system and boosts antioxidant defenses in the brain
  • Clinically researched and used for centuries to support brain and nervous system function
NON-GMO Project
Gluten Free
Vegan

$35.94 or subscribe and save 20%

In stock

Choose a purchase plan:

Bacopa Enlighten is a standardized extract of Bacopa monnieri, an herb used in traditional Ayurvedic medicine to support cognitive function and memory. In India, bacopa is often given to babies in the hopes that it will open the gateway to intelligence.

Bacopa has traditionally been used for improving cognitive functions such as those needed for math and memory skills, for decreasing angst and for reducing mental fatigue at work. It improves the processing of visual information to help increase the rate of learning, lower the rate of forgetfulness, and improve the ability to consolidate new information. Bacopa has also been studied in children with and without ADHD, and benefits have been shown in memory and learning in both scenarios.

Research has also shown promise for several key concerns of the aging brain.  Animal studies have shown that Bacopa prevents drug induced memory loss and increases protein synthesis in the brain as well as the production of key neural antioxidant enzymes, protecting brain cells from oxidative damage. Young or old, those who want to preserve healthy brain function and memory performance can benefit from Bacopa Enlighten.

AOR Advantage

Bacopa Enlighten is a high-dose extract of a traditional Ayurvedic plant that has been safely used for centuries to support the function of the brain. Clinical studies show it has protective effects on the brain and nervous system and has been found boost overall mental function.

NPN

80009764

Discussion

Bacopa Enlighten™ is Bacopa monnieri, a herb used in traditional Ayurvedic medicine to support healthy cognitive function.

Guarantee

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by product.

Adult Dosage

Take one capsule daily with or without food, or as directed by a qualified health care practitioner

Cautions

Do not use if pregnant or breastfeeding. Consult a health care practitioner for use beyond three months. May cause nausea, dry mouth and fatigue.

Main Applications
  • Cognitive support
  • Neuroprotection
  • Anti-aging
  • Memory
Disclaimer

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Capsule
Bacopa monnieri [Brahmi] extract (50% bacosides A&B)
300 mg

Non-medicinal Ingredients: microcrystalline cellulose and sodium benzoate. Capsule: hypromellose

Cognitive Health – Memory, Attention, Depression & Anxiety:
Study 1:
This double-blind, randomized, placebo-controlled, independently grouped clinical trial was carried out to investigate the effect on Bacopa monniera on the memory of older adults. Participants were randomized to receive either a placebo or bacopa (300 mg for persons under 90 kg, and 450 mg for persons over 90 kg, equivalent to 6g and 9g dried rhizome, respectively) for 3 months. There were three testing sessions: one prior to the trial, one after three months on the trial, and one six weeks after the completion of the trial to assess various memory functions.
The results showed a significant effect on bacopa supplementation on the retention of new information, thereby suggesting that bacopa is able to decrease the rate of forgetting newly acquired information. This was confirmed by the fact that the test for the rate of learning remained unaffected in the bacopa-supplemented group, compared to the placebo group.
https://www.nature.com/articles/1395862

Study 2:
This randomized, double-blind, placebo-controlled trial planned to evaluate the effects of bacopa supplementation on cognitive function in healthy, elderly, study participants. Participants were randomized to receive a placebo or bacopa (300 mg/day) for 12 weeks, with a placebo run-in of 6 weeks. Each participant was assessed by the following measures: Rey Auditory Verbal Learning Test (AVLT), Stroop Task assessing the ability to ignore irrelevant information, the Divided Attention Task (DAT), and the Wechsler Adult Intelligence Scale (WAIS) letter-digit test of immediate working memory. Affective measures were the State-Trait Anxiety Inventory, Center for Epidemiologic Studies Depression scale (CESD)-10 depression scale, and the Profile of Mood States. Vital signs were also monitored.
The results showed that bacopa supplementation enhanced AVLT delayed word recall memory scores, compared to the placebo group. Stroop results were similarly significant, with the Bacopa group improving and the placebo group unchanged. CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreased over time for the Bacopa group but increased for the placebo group. These results suggest that bacopa enhances cognitive performance and memory in the aging population.
https://pubmed.ncbi.nlm.nih.gov/18611150/

Study 3:
This double-blind, placebo-controlled, independent group designed clinical study evaluated the benefit of bacopa supplementation on cognitive function. Participants were randomized into a placebo group and a bacopa (150 mg, twice daily) group for 90 days and were assessed using neuropsychological testing by the Cognitive Drug Research cognitive assessment system at baseline and after 90 days of supplementation.
The results show improved performance on working memory, specifically spatial working memory accuracy. The number of false-positives recorded in the Rapid visual information-processing task was also reduced for the Bacopa monniera group following supplementation.
https://pubmed.ncbi.nlm.nih.gov/18683852/

Study 4:
This randomized, double-blind, placebo-controlled clinical study investigated the effectiveness of Bacopa monniera supplementation on memory performance in healthy older adults. Participants were randomized to receive a placebo or Bacopa, 300 mg per day for 12 weeks, and assessed for neuropsychologic and subjective memory assessment at baseline and after 12 weeks of supplementation. Audioverbal and visual memory performance were measured by the Rey Auditory Verbal Learning Test (AVLT), the Rey-Osterrieth Complex Figure Test (CFT), and the Reitan Trail Making Test (TMT). Subjective memory performance was measured by the Memory Complaint Questionnaire (MAC-Q).
The results showed that bacopa supplementation significantly improved verbal learning and memory acquisition, while delaying recall, total learning and retroactive interference, suggesting that bacopa supplementation may improve memory acquisition and retention in healthy older adults. Bacopa caused GIT side effects of increased stool frequency, abdominal cramps, and nausea; therefore, care should be taken with supplementation, by ensuring use of quality extracts.
https://pubmed.ncbi.nlm.nih.gov/20590480/

Study 5:
A randomized, double-blind, placebo-controlled clinical study aimed to study the effect of a standardized Bacopa monniera extract in individuals with age-associated memory impairment without evidence of dementia or other psychiatric disorders. Participants were randomized to receive a placebo or bacopa (125 mg) twice daily for 12 weeks, followed by placebo for another 4 weeks for a total study duration of 16 weeks. All individuals in the study were evaluated for changes in cognitive benefits, including mental control, logical memory, digit forward, digit backward, visual reproduction and paired associate learning.
Bacopa supplementation was associated with significant improvement in mental control, logical memory and paired associated learning during the 12-week supplementation period, suggesting that bacopa may provide cognitive health benefits in older adults with age associated memory impairment.
https://pubmed.ncbi.nlm.nih.gov/20703343/

Cognitive Health – Attention Deficit (Hyperactive) Disorder (ADD/ADHD):
Study 1:
The objective of this randomized, double-blind, placebo-controlled clinical trial was to evaluate the effect of an herbal mixture in improving attention, cognition, and impulse control in children with ADHD. The herbal mixture contained Paeoniae Alba, Withania Somnifera, Centella Asiatica, Spirulina Platensis, Bacopa Monnieri, and Melissa Officinalis. Children, aged 6-12 years old, were randomized in a 2:1 ratio (2X participants were assigned to the supplementation group) to receive a placebo or supplements for 4 months. Participants were assessed using the Test of Variables of Attention (TOVA) assessment before and after the supplementation period.
The results showed substantial, statistically significant improvement in the 4 subscales and overall TOVA scores, compared with no improvement in the control group, which persisted in an intention-to-treat analysis, suggesting that this combination of herbal products, including Bacopa may be helpful in improving attention, cognition and impulse control in children with ADHD.
https://pubmed.ncbi.nlm.nih.gov/20228219/

Study 2:
The aim of this open-label clinical study was to investigate the effectiveness of a standardized extract of Bacopa monnieri in improving the severity of ADHD symptoms. Children aged 6-12 years old, with an age of onset prior to 7 years of age were recruited for the study and received 225 mg bacopa extract daily for 6 months. Each child was assessed using the Parent Rating Scale at baseline and at the end of the 6-month supplementation.
The results show a significant reduction in subtest scores of ADHD symptoms, except for social problems, with bacopa supplementation. Symptoms of restlessness reduced in 93% of the children, improvement in self-control was observed in 89% of the children and overall attention-deficit symptoms were reduced in 85% of the participants. In addition, symptoms of learning problems, impulse control, and psychiatric problems were reduced by 78%, 67%, and 52% of children, respectively, suggesting that B. monnieri could be effective in alleviating the symptoms of ADHD.
https://pubmed.ncbi.nlm.nih.gov/24682000/